OBJECTIVE-We showed that 17␤-estradiol (E 2 ) favors pancreatic ␤-cell survival via the estrogen receptor-␣ (ER␣) in mice. E 2 activates nuclear estrogen receptors via an estrogen response element (ERE). E 2 also activates nongenomic signals via an extranuclear form of ER␣ and the G protein-coupled estrogen receptor (GPER). We studied the contribution of estrogen receptors to islet survival.
P
reserving insulin secretion by the pancreatic ␤-cells is critical in both type 1 and the late stages of type 2 diabetes. In type 1 diabetes, the death of insulin-producing ␤-cells of the pancreas by apoptosis leads to insulin dependence. Insulin replacement therapy by pancreatic islet transplantation is a treatment that most closely replicates normal physiological conditions for treatment of type 1 diabetes (1), but its effectiveness is reduced by the loss of functional islet mass from apoptosis, impairing the survival of islet grafts. Similarly, in the late stages of type 2 diabetes, evidence of ␤-cell apoptosis is documented in animal models (2, 3) and in humans (4) . Thus, in the absence of novel immunotherapy and antiapoptotic drugs, novel strategies to protect insulin-producing cells in vivo represent a major opportunity for therapeutic intervention. One promising approach to protect ␤-cells from apoptosis involves the cytoprotective actions of estrogens. In addition to its reproductive functions, the female sex steroid 17␤-estradiol (E 2 ) is a neuroprotective hormone against multiple oxidative and proapoptotic insults in vivo and in vitro, acting via classic estrogen receptors (rev. in 5). Recently, we reported that E 2 protects ␤-cells from streptozotocin (STZ)-induced apoptosis in mice of both sexes via the estrogen receptor (ER)-␣ (6) . In cultured mouse and human islets, E 2 has potent antiapoptotic properties against proinflammatory cytokines and reactive oxygen species (6, 7) . E 2 acts via classic estrogen receptors, ER␣ and ER␤ (8) . In ER␣-deficient female mice, E 2 still partially protects ␤-cell survival via an alternative pathway (6) , suggesting that ER␤ may mediate the effects of E 2 in the absence of ER␣.
The G protein-coupled estrogen receptor (GPER), also known as GPR30, has been recognized as a membrane receptor for estrogens that mediates nongenomic signals (9) . GPER is expressed in islets and has recently been suggested to mediate the estrogenic effect on islet insulin release (10) . We analyzed the contribution of ER␣, ER␤, and GPER to islet survival. We used mice individually deficient in ER␣, ER␤, ER␣ and ER␤, and GPER; a mouse lacking ER␣ binding to the ERE; and human islets. These mutant mice and islets were exposed to oxidative stress using STZ or hydrogen peroxide, respectively, in combination with the use of specific pharmacological probes.
by crossing heterozygote male ␣ERKO AA/ϩ with heterozygote female ER␣ null mice (␣ERKO ϩ/Ϫ ). Because female ␣ERKO AA/ϩ are infertile, they cannot be crossed with male ␣ERKO AA/ϩ , and therefore ␣ERKO AA/AA mice cannot be generated. All animal experiments were approved by Northwestern University Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Animals. Metabolic studies. Glucose tolerance tests (2 g/kg) and corresponding area under the curve for glucose (minus basal) and glucose-stimulated insulin secretion (3 g/kg) were performed as described (6) . Serum insulin concentrations were measured by ELISA using mouse standards (Crystal Chem, Chicago, IL) (6) . Exogenous substance infusion and induction of experimental diabetes. Diabetes was induced in 8-week-old female mice by a single intraperitoneal injection of 150 mg/kg of STZ as described (6) . Blood glucose was measured every 48 h after STZ injection with a glucose monitor. At day 8 after STZ injection, mice were killed and pancreata collected. Pancreas insulin concentration. Whole pancreata were collected, weighed, and homogenized in acid/ethanol. Pancreas homogenates were centrifuged, and the supernatant was used to measure pancreas insulin concentration by radioimmunoassay (6) . Islet culture and compounds stimulation. Islet isolation was performed as previously described (6) . Islets were cultured in phenol red-free RPMI medium containing 11 mmol/l glucose, 10% charcoal stripped FBS, 1 mmol/l glutamine, 100 units/ml penicillin, 100 g/ml streptomycin. Islets were incubated with E 2 (10 Ϫ8 M, steraloids), propyl-pyrazole-triol (PPT, 10 Ϫ8 M) (13), methylpiperidino-pyrazole (MPP, 10 Ϫ7 M) (14) , diarylpropionitrile (DPN, 10 Ϫ8 M) (15), tetrahydrochrysene (THC, 10 Ϫ7 M) (16), estrogen-dendrimer conjugate (EDC) (10 Ϫ8 M) (17) or G-1 (10 Ϫ7 M) (18) for 48 h. Ethanol was used as the vehicle. After 48 h estrogen receptor ligands treatment, islets were exposed to H 2 O 2 (100 mol/l, Sigma) for the last 5 h before assessment of apoptosis. PPT, EDC, and DPN were a gift from John A. Katzenellenbogen, University of Illinois at Urbana. Antibodies. In immunohistochemical studies, the following primary antibodies were used: guinea pig anti-insulin (1:1,000, Linco Research), rabbit anti-glucagon (1:1,000, Linco Research), mouse anti-ER␣ (1:100, 1D5, Zymed Laboratories), and goat anti-ER␤ (1:100, Y-19, Santa Cruz Biotechnology). Where tyramide signal amplification was performed, biotinylated secondary antibodies were used. Where signal was not amplified, FITC-or Cy3-conjugated secondary antibodies were used. Secondary antibodies were raised in donkey (Jackson ImmunoResearch) and used at a 1:200 dilution. Immunohistochemistry. Mouse pancreases were fixed and processed for immunohistochemistry as described (6) . For staining with ER␣ and ER␤, Alexa 568 tyramide signal amplification kit (Molecular Probes) was used. Sections were counterstained with DAPI (1:50,000, 5 min) before confocal visualization (Zeiss LSM 510). For MIN6 immunolabeling, cells were seeded on coverslips and grown until ϳ80% confluency. Twenty four hours before fixation, cells were maintained in phenol red-free DMEM media (Sigma). Cells were treated with E 2 (10 Ϫ8 M) or ethanol vehicle for 1 h, washed with warm PBS, and fixed in 10% neutral-buffered formalin for 20 min. For labeling of mitochondria, live cells were incubated for 45 min with 100 nmol/l MitoTracker reagent (Molecular Probes). Cells were permeabilized (0.1% Triton X-100/PBS), blocked (1 h, 5% normal donkey serum), labeled with antibodies, counterstained, and visualized with confocal or deconvolution (Applied Precision DeltaVision) microscopy. Measurement of apoptosis by nuclear morphology. Apoptosis was induced by H 2 O 2 (100 mol/l, 5 h) in groups of 100 islets per condition. After 5 h incubation with H 2 O 2 , islets were collected and washed with PBS. Single-cell suspensions were obtained by incubating the islets in 500 l Accutase solution (Innovative Cell Technologies, San Diego, CA) at 37°C for 15 min, followed by gentle pipetting. To score apoptosis, cells were fixed with 1.25% glutaraldehyde for 15 min at room temperature and nuclei were stained with 10 g/ml bisbenzimide (Hoechst 33258; Sigma) for 15 min at room temperature. The percentage of cells with apoptotic nuclei (condensed or fragmented) was determined by fluorescence microscopy (E400 Nikon Eclipse). For each condition, at least 200 cells were scored in duplicate. Results are representative of at least three independent experiments. Assay for active caspase 3. Caspase activity was measured in mouse islets using Caspase-Glo 3/7 assay kit (Promega). Briefly, after 5 h incubation with H 2 O 2 (100 mol/l, Sigma), islets were centrifuged for 5 min at 1,200 rpm and transferred to a 96-well plate in 100 l medium. Islets were then lysed with 100 l Caspase-Glo 3/7 reagent and incubated at room temperature for 30 min. Luciferase activity was measured using a Synergy 2 Multi-Mode Microplate Reader (BioTek). Values are reported as relative luciferase units corrected for total protein concentration. Plasmid transfection and luciferase assay. MIN6 cells were cultured in DMEM high medium and plated in 24-well plates (10 ϫ 10 4 cells/well). Before the transfection, cells were cultured overnight in DMEM phenol red-free medium. Cells were incubated with the mixture of 2 l Lipofectamine 2000 (Invitrogen) and 0.8 g of a reporter construct containing an ERE (ERE-Luc) for 6 h (19). Cells were treated for 24 h with either E 2 (10 Ϫ8 M), E 2 -BSA (10 Ϫ8 M), EDC (10 Ϫ8 M), or G1 (10 Ϫ7 M). For measurement of luciferase activity, cells were lysed with Cell Culture Lysis Reagent (Promega). After centrifugation, 2-6 g of protein were used in a Luciferase Assay System (Promega). Values are reported as relative luciferase units corrected for total protein concentration. Western blot analysis. Cells were homogenized in lysis buffer as described (20) . Thirty micrograms of protein was analyzed by SDS-PAGE. Cytoplasmic and nuclear fractions were extracted using a commercial kit (Pierce Biotechnology), and ER␣ expression was determined by immunoblotting with mouse anti-ER␣ antibody (1:100, MC-20, Santa Cruz Biotechnology). GPER expression was determined by immunoblotting with a polyclonal goat anti-GPR30 antibody (1:400, Santa Cruz Biotechnology). Statistical analysis. Results are presented as means Ϯ SE unless otherwise stated. Data were analyzed using the unpaired Student's t test. Cumulative incidence of diabetes was determined by Kaplan-Meier estimates, and statistical analysis of differences was determined by log-rank test. A value of P Ͻ 0.05 was considered significant.
RESULTS
ER␣ protects islet survival independently of the classic estrogen response element. We previously reported that ER␣-deficient mice lose cytoprotection from circulating E 2 and are predisposed to ␤-cell apoptosis when their islets are exposed to oxidative stress in vivo (6) . In the classic estrogen receptor signaling pathway, E 2 -activated ER␣ binds as a homodimer to either an ERE or a non-ERE tethered promoter to initiate gene transcription (21) . To investigate whether an ER␣-ERE or non-ERE signaling mechanism protects ␤-cell survival in vivo, we used an ER␣ knock-in mouse with a mutation of the DNA-binding domain of ER␣ that eliminates ER␣ binding to the ERE (␣ERKO AA/Ϫ ) (12) . To produce ␤-cell apoptosis in vivo, we used a single high-dose injection of STZ (150 mg/kg) in female mice. STZ provokes an increase in islet reactive oxygen species as can be encountered after exposure to hyperglycemia or cytokines in type 1 diabetes and type 2 diabetes (22, 23) . We compared the sensitivity to STZ in ␣ERKO AA/Ϫ mice with one knock-in AA allele with that of ␣ERKO ϩ/Ϫ and ␣ERKO Ϫ/Ϫ mice with one or no functional ER␣ allele. This enabled us to study the effect of the unique AA allele and non-ERE signaling on the predisposition to ␤-cell apoptosis in vivo. Compared with the null ␣ERKO Ϫ/Ϫ , the ␣ERKO ϩ/Ϫ showed a minor predisposition to STZ-induced insulin-deficient diabetes, confirming a minor effect of ER␣ gene dosage (6) . A single AA allele without ERE binding was sufficient to protect ␣ERKO AA/Ϫ female mice from STZ-induced insulin-deficient diabetes to an extent similar to that observed in ␣ERKO ϩ/Ϫ mice ( Fig. 1A-D) , demonstrating that ER␣ protection of ␤-cell survival is independent of the classic ERE-dependent pathway. ER␣ prevents islet apoptosis via rapid, extranuclear actions. Because activation of ER␣ protects ␤-cell survival via an ERE-independent mechanism, we explored the possibility that ER␣ favors survival through rapid, extranuclear actions. We observed colocalization of ER␣ with insulin-producing ␤-cells in mouse and human pancreatic islets with a predominant cytosolic localization ( Fig. 2A and B) . In mouse MIN6 ␤-cells, we observed ER␣ predominantly in the cytosol, in close vicinity to the plasma membrane and mitochondria ( Fig. S1A and B, available in an online appendix at http://diabetes. diabetesjournals.org/content/early/2009/07/08/db09-0257/ suppl/DC3). The predominant cytosolic localization of ER␣ in ␤-cells, although it exhibits a predominant nuclear localization in reproductive tissues (supplemental Fig.  S1C , available in an online appendix), suggested that ER␣ regulates ␤-cell biology through extranuclear signaling pathways. To explore that hypothesis, we first studied the subcellular localization of ER␣ by confocal microscopy in MIN6 ␤-cells. In the absence of E 2 , ER␣ showed a dual cytosolic and nuclear immunoreactivity (Fig. 2C ). E 2 stimulation for 1 h provoked a disappearance of nuclear ER␣ immunoreactivity and an increased density of ER␣ extranuclear signal (Fig. 2C ). This pattern was similarly observed using two different ER␣ antibodies (supplemental Fig. S2 , available in an online appendix). To explore the mechanism of alteration in ER␣ signal between cytosol and nucleus, we performed subcellular fractionation in MIN6 cells. After E 2 stimulation, we observed no change in the amount of the classic 67kDa ER␣ isoform between the nucleus and cytosolic fractions (Fig. 2D ), demonstrating that there is no transfer of ER␣ from the nucleus to the cytosol. The E 2 -induced alteration of ER␣ nuclear signal into irregular punctuate structures was interpreted as an organization of nuclear speckles symbolic of active transcription start sites in fluorescent microscopy (24) . A similar appearance was observed after E 2 stimulation in a classic model of ER␣ nuclear actions, the human breast cancer MCF7 cells (supplemental Fig. S1E , available in an online appendix). We hypothesized that the increased ER␣ extranuclear signal upon E 2 stimulation was a sign of ER␣ extranuclear and antiapoptotic signaling that is dissociated from ER␣ nuclear presence. To address this latter possibility, we studied E 2 protection from apoptosis in cultured islets after acute exposure to H 2 O 2 (100 mol/l) to mimic the oxidative injury observed in vivo after exposure of islets to a single high dose of STZ (25) . We used two pharmacological probes specific for estrogen receptor nongenomic actions: 1) A membrane-impermeant preparation of E 2 , which is bound to a macromolecule, namely, BSA (E 2 -BSA). The response to the membraneimpermeant compounds is used as a gold standard to define membrane-initiated responses (26) (Fig. 2E) . Exposure of mouse and human islets to E 2 , E 2 -BSA, or EDC produced a similar and robust protection against H 2 O 2 -induced apoptosis ( Fig. 2F and G) . Elimination of ER␤ mildly predisposes to STZinduced diabetes. In ␣ERKO Ϫ/Ϫ mice, E 2 still partially protects ␤-cell survival via an alternative pathway (6), making ER␤ a candidate for mediating the effects of E 2 in the absence of ER␣. We observed ER␤ expression in mouse and human pancreatic ␤-cells and MIN6 cells with a cytosolic localization (Fig. 3A-C) , although it exhibits a predominant nuclear localization in reproductive tissues (supplementary Fig. S1D , available in an online appendix). ER␤ localization was not influenced by E 2 treatment (supplementary Fig. S3 , available in an online appendix). We sought to determine whether ER␤ exerts E 2 protection of ␤-cell survival using ER␤-deficient mice (␤ERKO Ϫ/Ϫ mice). In basal condition, female ␤ERKO Ϫ/Ϫ mice showed no abnormality of fasting and fed blood glucose (supplemental Table 1 , available at an online appendix). After exposure to STZ, as previously described (6), female wild-type mice were protected and retained normal blood glucose and pancreas insulin concentrations; conversely, female ␤ERKO Ϫ/Ϫ mice were vulnerable to STZ and exhibited mild hyperglycemia and moderate insulin deficiency compared to wild type (Fig. 3 D-G) . Male wild-type and ␤ERKO Ϫ/Ϫ mice were exposed to a less diabetogenic single low dose of STZ (100 mg/kg). Such a low dose of STZ caused a moderate increase in diabetes incidence in male wild-type mice, while it predisposed to insulindeficient diabetes in male ␤ERKO Ϫ/Ϫ mice (supplementary Fig. S4 , available in an online appendix). E 2 protects islet survival in the absence of ER␣ and ER␤ in mice. Because individual deletion of ER␣ and ER␤ impairs islet resistance to STZ in mice, we hypothesized that combined elimination of both ER␣ and ER␤ would synergize to abolish E 2 protection of islet survival. We thus compared the role of ER␣ and ER␤ in islet survival from STZ injury in the single ␣ERKO Ϫ/Ϫ , ␤ERKO Ϫ/Ϫ , and the double ␣␤ERKO Ϫ/Ϫ littermate female mice. We confirmed that exposure to STZ caused a more severe predisposition to insulin-deficient diabetes in female ␣ERKO Ϫ/Ϫ mice compared to littermate ␤ERKO Ϫ/Ϫ mice ( Fig. 4A-D) . However, after exposure to STZ, the dual absence of ER␣ and ER␤ in the double ␣␤ERKO Ϫ/Ϫ did not aggravate the predisposition to insulin-deficient diabetes, suggesting that in the absence of both estrogen receptors, E 2 still protects via an alternative pathway (Fig. 4A-D) . Thus, to determine the extent to which, in the absence of ER␣ and ER␤, circulating E 2 could still protect the ␣␤ERKO Ϫ/Ϫ , we suppressed endogenous E 2 production by ovariectomy (OVX). OVX further aggravated the predisposition to STZ in female ␣␤ERKO Ϫ/Ϫ mice while, conversely, E 2 treatment of ␣␤ERKO Ϫ/Ϫ OVX mice restored protection from STZ-induced insulin-deficient diabetes (Fig. 4A-D) . Similar findings were observed in male mice. The double ␣␤ERKO Ϫ/Ϫ mice did not show a more severe predisposition to STZ compared to the single ␣ERKO Ϫ/Ϫ and ␤ERKO Ϫ/Ϫ male littermates (supplementary Fig. S5 , available in an online appendix). E 2 protects islet survival in the absence of ER␣ and ER␤ in vitro. The individual contribution of ER␣ and ER␤ to islet survival was next examined in cultured wild-type mouse islets using PPT and DPN, which are ER␣-and ER␤-selective agonists, respectively (13, 15) . After induction of apoptosis with H 2 O 2 , we observed a similar prevention of apoptosis by E 2 and PPT treatments (Fig. 5A) ; accordingly, E 2 protection was impaired using the ER␣-selective antagonist MPP (Fig. 5A) (14) . DPN provided only minor islet protection, but E 2 protection from islet apoptosis was impaired using the ER␤-selective antagonist THC (Fig. 5A ). We next examined E 2 protection of islet survival in ER␣-and ER␤-deficient mouse islets. H 2 O 2 provoked an increase in apoptotic cells from wild-type islets, which was prevented by E 2 (Fig. 5B ). E 2 protection was impaired in ␣ERKO Ϫ/Ϫ islets. Conversely, E 2 protection was retained in ␤ERKO Ϫ/Ϫ islets. In addition, consistent with the in vivo data, in the absence of both ER␣ and ER␤, E 2 protection of apoptosis was retained in ␣␤ERKO Ϫ/Ϫ islets (Fig. 5B ). E 2 antiapoptotic action via ER␣ and ER␤ was further investigated using a luminescent assay for activated caspase-3, the "executioner" of apoptosis. E 2 prevented caspase-3 activation that was mimicked by PPT and DPN treatment. However, E 2 prevention of caspase-3 activation was abolished in ␣ERKO Ϫ/Ϫ islets but was retained in ␤ERKO Ϫ/Ϫ islets (Fig. 5C ). We also observed that E 2 , PPT, and to a lesser extent DPN protect human islets from H 2 O 2 -induced apoptosis (Fig. 5D) . Lastly, the antiapoptotic protection of E 2 and PPT was reproduced in MIN6 cells demonstrating a direct effect on ␤-cells (Fig. 5E) . Thus, E 2 protects ␤-cell survival in vivo and in cultured islets via ER␣ and ER␤, with a predominant ER␣ effect. However, in the absence of ER␣ and ER␤, E 2 still protects ␤-cell survival. GPER is important for islet survival. Recently, GPER, also known as GPR30, has been recognized as a membrane receptor for estrogens that mediates nongenomic, rapid signals (9, 27) . We observed that GPER protein is expressed in mouse islets, human islets, and MIN6 cells (Fig.  6A) . Because E 2 protects ␤-cell survival via a membraneinitiated mechanism (Fig. 2F and G) and in the absence of ER␣ and ER␤ (Fig. 4 and 5) , we investigated the possibility that E 2 cytoprotection is mediated via GPER. We investigated the importance of GPER using mice deficient in the receptor (GPERKO Ϫ/Ϫ ). When studied on a regular chow, female wild-type and GPERKO Ϫ/Ϫ littermate mice showed similar fasting and fed blood glucose and serum insulin concentrations (Table 1) . We observed no difference between wild-type and female GPERKO Ϫ/Ϫ mice with regard to intraperitoneal glucose tolerance, glucose-stimulated insulin secretion, fed pancreas insulin concentrations (Table 1), and islet architecture (supplementary Fig S6, available in an online appendix). However, after exposure to STZ, compared to wild-type female mice, GPERKO Ϫ/Ϫ female mice lost the protection of endogenous E 2 and
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were predisposed to insulin-deficient diabetes leading to loss of ␤-cells and decrease in pancreas insulin concentration (Fig. 6B-F) . The predisposition to STZ-induced diabetes was not observed in male GPERKO Ϫ/Ϫ mice (supplementary Fig S7, available in an online appendix) . We next studied the importance of GPER in cultured pancreatic islets from wild-type and GPERKO Ϫ/Ϫ mice. We used the GPER agonist G1, which selectively activates GPER in a cellular environment containing ER␣ and ER␤ (18) . G1 showed no transactivating activity on ERE-dependent gene expression in ␤-cells (Fig. 6G) . We found that G1 prevents apoptosis as efficiently as E 2 in wild-type mouse islets and human islets (Fig. 6H and J) . We observed that E 2 cytoprotection, measured either via nuclear morphology or caspase-3 activation, was retained in mouse GPERKO Ϫ/Ϫ islets compared to wild-type islets, demonstrating that ER␣ can compensate for the absence of GPER in GPERKO Ϫ/Ϫ islets ( Fig. 6H and I) . Conversely, G1 cytoprotection was abolished in GPERKO Ϫ/Ϫ islets, demonstrating its high selectivity toward GPER compared with ER␣ and ER␤ (Fig. 6H and I) . We confirmed that G1 protection from apoptosis was observed in human islets (Fig. 6J) and that G1 directly acts on ␤-cells (Fig. 6K) . Thus, E 2 protection is mediated via ER␣, ER␤, and GPER with a direct effect on the islets and with a predominant ER␣ effect, via ERE-independent, extranuclear, and rapid mechanisms.
DISCUSSION
Recently, we reported that E 2 protects ␤-cell survival in mice of both sexes via ER␣ (6). Many actions of E 2 , including the feminizing effects, are mediated via a classic and nuclear ER␣-activating transcription through an ERE (21) . Here, using a mouse model lacking ERE signaling, we show that ER␣ cytoprotection of islets in vivo is ERE independent. Both ER␣ and ER␤ show cytosolic localization in ␤-cells, and we find that E 2 favors ␤-cell survival via activation of extranuclear and perhaps membrane estrogen receptors with a predominant ER␣ effect. This finding extends the observation of Kousteni et al. (28) , suggesting that the antiapoptotic actions of E 2 in osteoblasts and fibroblasts are mediated via the ligand-binding domain of ER␣ and ER␤ with similar efficiency, and can be dissociated from the transcriptional activity of the receptors. Thus, unlike in classic estrogen receptor genomic actions where E 2 -activated ER␣ and ER␤ signal in opposite ways from an AP1 element (29) , with regard to extranuclear, antiapoptotic actions, ER␣ and ER␤ signal survival in similar direction. Indeed, the coexpression of both ER␣ and ER␤ in ␤-cells does not demonstrate evidence of ER␤ antagonism of ER␣ action because pharmacological inhibition or genetic elimination of ER␤ in islets does not enhance E 2 cytoprotection via ER␣. However, despite the apparent antiapoptotic action of ER␣ and ER␤, the combined elimination of these receptors does not synergize to abolish E 2 cytoprotection after exposure of islets to acute oxidative stress. This suggests that ER␣ and ER␤ favor islet survival using nonredundant and distinct cellular pathways.
The second important finding is that the membrane G protein-coupled receptor, GPER, favors islet survival. GPER is a 7-transmembrane orphan G protein-coupled receptor that responds to E 2 with rapid cellular signaling (9) . GPER has been localized to either the plasma membrane (30) or the endoplasmic reticulum (9) . The physiological function of GPER in vivo is still largely unknown. The existence of a membrane G protein-coupled receptor unrelated to ER␣ and ER␤ and that may be GPER has been reported in ␤-cells (31, 32) . Recently, Martensson et al. (10) reported that GPER-deficient mice display altered E 2 -stimulated insulin release from isolated islets associated with impaired glucose-stimulated insulin secretion in vivo, suggesting that GPER is involved in islet biology. Because E 2 protects ␤-cell from apoptosis (6,7) and recent studies have implicated GPER in cell survival (33, 34) , we hypothesized that GPER favors ␤-cell survival. We observe that GPER deficiency in female mice does not alter ␤-cell function or glucose homeostasis on a normal rodent chow. This different phenotype with the previous report (10) may be related to the different genetic background of the mice used in both studies and/or the greater ability of our GPERKO Ϫ/Ϫ mice to compensate for the loss of GPER via ER␣. We find that elimination of GPER predisposes to STZ-induced islet apoptosis after exposure to acute oxidative stress in female mice. In addition, we show that pharmacological activation of GPER by G1 is efficient in protecting oxidative stress-induced apoptosis in cultured islets. The observation that G1 cytoprotection is lost in cultured GPER-deficient islets further supports the functional significance of GPER in islet survival. However, the maintenance of E 2 cytoprotection from apoptosis in cultured GPER-deficient islets demonstrates that ER␣ and ER␤ can compensate for GPER deficiency. Conversely, we confirm that E 2 cytoprotection is impaired in ER␣-deficient islets and can be compensated, only partially, by GPER or ER␤. Thus, ER␣ is the major E 2 receptor to favor islet survival in mice.
A recent report has challenged the initial concept that GPER is indeed an estrogen receptor in vivo based on the observation that loss of GPER in mice does not alter estrogenic responses in reproductive organs that express GPER (35) . However, other investigators reported that GPER mediates estrogen action in mice. For example, GPER is necessary for the normal estrogenic response on longitudinal bone growth (36) . In addition, GPER-deficient mice lose E 2 -stimulated insulin release, arguing that GPER mediates E 2 response in pancreatic islets (10) . Thus, when referring to in vivo models, GPER appears to mediate E 2 response in several tissues. E 2 binds a membrane-localized ER␣, which signals through a large protein signalosome at the plasma membrane. This complex consists of scaffold proteins (caveolin-1, MNAR), linker proteins (Shc), nonreceptor tyrosine kinases (Src), threonine/serine kinases (p85 subunit of PI3 kinase, Akt), and growth factor receptors (EGFR, IGF1R) (37) . It is possible that membrane-localized ER␣ signals by recruiting GPER from the endoplasmic reticulum or the plasma membrane (38) . Our studies do not rule out this latter possibility because a membrane-impermeant formulation of E 2 (E 2 -BSA) is as efficient as E 2 or the selective ER␣ agonist PPT in protecting islet survival. Thus, E 2 could either bind a membrane ER␣, which would then signal through GPER, or both ER␣ and GPER, together utilizing the same signaling pathway. Studies are ongoing in our laboratory to dissect the signaling pathways of estrogen receptor cytoprotection in ␤-cells.
The protection by E 2 described here in vivo in global estrogen receptor-deficient mice reflects the loss of estrogen receptor signaling in all tissues that express these receptors. Therefore, alteration in interorgan communication and metabolic regulation because of loss of estrogen receptors in a distant organ may also indirectly impair islet survival via circulating factors without a direct effect of E 2 on ␤-cells. For example, the predisposition to STZ observed in vivo in estrogen receptor-deficient mice could be enhanced by subtle differences in glucose concentration or adipose production of proinflammatory cytokines (39) . However, the therapeutic effects of estrogen receptor ligands obtained in cultured human islets have therapeutic implications in islet transplantation. The feminizing effects of estrogens limit their clinical application to protect islet survival in men and in some women. However, the observation that E 2 utilizes extranuclear and membrane pathways that are sex nonspecific may help identify and develop new ligands that protect ␤-cells and allow retention of the beneficial effects of sex hormones in islets while lacking the mitogenic actions predisposing to hormone-dependent cancers.
In summary, E 2 plays a major role in protecting ␤-cells from apoptosis that is mediated through ER␣, ER␤, and GPER. The present study adds a novel dimension to estrogen biology in ␤-cells and identifies GPER as a new target to protect islet survival. Results represent the means Ϯ SE. n.s., nonsignificant.
